Reports record revenue, improves adjusted EBITDA, raises full-year guidance Second quarter and recent highlights Delivered record total second quarter revenue of $811 million, an increase of 16% on a reported and core revenue basis, including Screening revenue of $628 million and Precision Oncology revenue of $183 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $55 million and $25 million,... Read More

Exact Sciences acquires exclusive rights to current and future versions of Freenome’s blood-based colorectal cancer screening tests Freenome submitted the final module of the premarket approval application to the FDA for the first-version test Strengthens Exact Sciences’ leadership in colorectal cancer screening by adding blood-based testing to complement Cologuard MADISON, Wis. / Aug 06, 2025 / Business Wire / Exact... Read More

Cologuard Plus™ Available In-Network August 2025 MADISON, Wis. / Jul 31, 2025 / Business Wire / Exact Sciences Corp . (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance access to colorectal cancer (CRC) screening. Through the partnership, the Cologuard Plus™ test will be available as an in-network service for eligible Humana... Read More

MADISON, Wis. / Jul 14, 2025 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results... Read More

MADISON, Wis. / Jul 09, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX) for serial use in patients with stage II, III and resectable stage IV... Read More

Beta-CORRECT study to be presented at ASCO 2025 confirms the clinical utility of the molecular residual disease (MRD) test, Oncodetect™, for recurrence monitoring in stage II–IV colorectal cancer Whole-genome Oncodetect test powered by MAESTRO to launch in 2026 with ultra-low limit of detection 1 MADISON, Wis. / May 28, 2025 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and... Read More

MADISON, Wis. / May 27, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. William Blair 45th Annual Growth Stock Conference, Chicago Presentation on Tuesday, June 3, 2025 at 9:40 a.m. ET The webcast can be accessed in the... Read More

MADISON, Wis. / May 22, 2025 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD) test, multi-cancer early... Read More

Award marks seventh consecutive year company has received prestigious distinction MADISON, Wis. / May 12, 2025 / Business Wire / Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® for the seventh consecutive year in the U.S., and for the first time in the U.K., Japan, Canada, France, Italy, Poland, and Germany.... Read More

MADISON, Wis. / May 02, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a.m. PT) The webcast can be... Read More

First quarter highlights Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of $540 million and Precision Oncology revenue of $167 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively Launched the Cologuard Plus™ test, the company's next-generation colon cancer... Read More

Robust research and data from multiple abstracts predict the Cologuard® test as the top choice for screening average-risk adults 45 and older, and confirms adoption across diverse demographics MADISON, Wis. / Apr 29, 2025 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present 15 abstracts during Digestive Disease Week (DDW)... Read More

The new, highly sensitive, tumor-informed test detects up to 200 ctDNA* variants, identifying signs of colorectal cancer (CRC) recurrence up to two years earlier than imaging—making it one of the most comprehensive MRD tests available 1,2 The Oncodetect test is available for order across multiple solid tumors † MADISON, Wis. / Apr 22, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer... Read More

Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity MADISON, Wis. / Apr 14, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in JAMA Oncology that... Read More

MADISON, Wis. / Apr 01, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and... Read More

The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date MADISON, Wis. / Mar 31, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Cologuard Plus ™ , the most accurate noninvasive colorectal... Read More

MADISON, Wis. / Mar 12, 2025 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2025 Gallup Exceptional Workplace Award (GEWA), marking the second year in a row the company has received this prestigious recognition. This award recognizes the most engaged workplace cultures in the world. Gallup created the Exceptional... Read More

MADISON, Wis. / Feb 24, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. TD Cowen Health Care Conference, Boston Fireside chat on Monday, March 3, 2025 at 10:30 a.m. ET Raymond James Institutional Investors Conference,... Read More

Fourth quarter and 2024 highlights Total fourth quarter revenue of $713 million, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $553 million and Precision Oncology revenue of $161 million Total 2024 revenue of $2.76 billion, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $2.10 billion and Precision Oncology revenue of $655 million Plans to launch three new cancer... Read More

CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the “Board”), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible... Read More

MADISON, Wis. / Feb 03, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results... Read More

Results from prospective molecular residual disease (MRD) study show a positive Oncodetect test result is strongly associated with recurrence in stage III colon cancer patients Oncodetect test achieved the primary endpoint in a second clinical validation study, extending its prognostic value into stages II and IV colon cancer and rectal cancer Exact Sciences plans to launch the Oncodetect test in Q2 2025 with Medicare... Read More

Circulating tumor DNA (ctDNA) analysis and advanced tumor profiling in GI cancers highlight opportunities for recurrence monitoring and targeted therapy selection Modeling analyses and real-world evidence further demonstrate the impact of Cologuard® screening through precancer detection and high-test completion rates MADISON, Wis. / Jan 21, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of... Read More

Highlighted announcements: Expects total fourth quarter revenue of $713 million, an increase of 10% compared to the fourth quarter of 2023, with Screening revenue of $553 million and Precision Oncology revenue of $161 million Anticipates total full-year 2024 revenue of $2.76 billion, an increase of 10% compared to full-year 2023 Plans to launch three new cancer tests in 2025: Cologuard Plus TM , next-generation colorectal... Read More

MADISON, Wis. / Jan 02, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. J.P. Morgan Healthcare Conference, San Francisco Presentation followed by Q&A on Monday, January 13, 2025 at 1:30 p.m. ET The webcast can be accessed... Read More

MADISON, Wis. / Nov 26, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Citi Global Healthcare Conference, Miami Fireside chat on Tuesday, December 3, 2024 at 8:45 a.m. ET Evercore HealthCONx Conference, Miami Fireside... Read More

New data supports the value of the Oncotype DX Breast Recurrence Score ® test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally MADISON, Wis. / Nov 25, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the... Read More

New evidence shows multi-biomarker class approach improved cancer detection, including in earlier stages when treatment may be more effective Modeling data estimate adding MCED testing to standard-of-care screening could reduce cancer mortality by 17% New analysis from DETECT-A study supports MCED testing as a complement to current guideline-recommended screening MADISON, Wis. / Nov 13, 2024 / Business Wire / Exact Sciences... Read More

Delivered record revenue and cash flow, improved adjusted EBITDA, advanced pipeline Third quarter highlights Total third quarter revenue of $709 million, an increase of 13% on a reported and core revenue basis, including Screening revenue of $545 million and Precision Oncology revenue of $164 million Net loss was $38 million, adjusted EBITDA was $99 million, and adjusted EBITDA margin increased 500 basis points to 14%... Read More

MADISON, Wis. / Nov 01, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. Jefferies London Healthcare Conference, London Fireside chat on Tuesday, November 19, 2024 at 6:00 a.m. ET The webcast can be accessed in the... Read More

Modeling data show Cologuard Plus TM test delivers highest life-years gained with fewest number of colonoscopies among noninvasive colorectal cancer (CRC) screening strategies Additional abstracts support real-world expertise and experience in increasing patient adherence, especially in underserved populations MADISON, Wis. / Oct 27, 2024 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer... Read More

MADISON, Wis. / Oct 08, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on November 5, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results... Read More

Cologuard Plus™ test raises the performance bar with sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity Cologuard Plus test will minimize unnecessary follow-up colonoscopies by reducing the likelihood of a false-positive screening test Company expects to launch Cologuard Plus test with Medicare coverage and guideline inclusion in 2025 MADISON, Wis. / Oct 04, 2024 /... Read More

Data presented show sensitivities of 88% for colorectal cancer and 31% for advanced precancerous lesions at 90% specificity Scientific insights reflect Exact Sciences’ commitment to closing the screening gap through innovation Results shared alongside evidence supporting multi-cancer early detection approach MADISON, Wis. / Sep 16, 2024 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer... Read More

MADISON, Wis. / Aug 28, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Wells Fargo Healthcare Conference, Boston Fireside chat on Wednesday, September 4, 2024 at 3:45 p.m. ET Baird Global Healthcare Conference, New York... Read More

Primary study sites Baylor Scott & White Health in Texas and Endeavor Health in Illinois aim to enroll up to 25,000 patients from diverse backgrounds, assessing the impact of MCED testing on clinical care Falcon Registry study is another step in Exact Sciences’ rigorous approach to develop its future multi-biomarker class blood-based MCED test MADISON, Wis. / Aug 20, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq:... Read More

Data demonstrate long-term impact of the Cologuard test, a powerful tool for preventing and detecting cancer MADISON, Wis. / Aug 15, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, shared new modeling data today describing the projected impact of the Cologuard test on patients, health care professionals, and the U.S. health care system since its FDA... Read More

Reports record results, screened more than 1 million people with Cologuard ® , raises adjusted EBITDA guidance Second quarter highlights Delivered total second quarter revenue of $699 million, an increase of 12%, or 13% on a core revenue basis, including Screening revenue of $532 million and Precision Oncology revenue of $168 million Screened more than 1 million people with Cologuard for the first time during a quarter and... Read More

SEATTLE , July 31, 2024 /PRNewswire/ -- TwinStrand Biosciences today announced an agreement with Exact Sciences (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, to exclusively license its patent estate in the cell free nucleic acid sequencing space, including its patent portfolios licensed from the University of Washington and the University of Texas Southwestern. The license is related to... Read More

MADISON, Wis. / Jul 08, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and... Read More

MADISON, Wis. / May 28, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. William Blair 44 th Annual Growth Stock Conference, Chicago Presentation on Tuesday, June 4, 2024 at 1:40 p.m. ET Jefferies Healthcare Conference,... Read More

Data to be presented expands the body of evidence around the predictive and prognostic value of the Oncotype DX ® test in all racial and ethnic groups New data showcase Exact Sciences’ commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients MADISON, Wis. / May 24, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer... Read More

Award marks sixth consecutive year company has received prestigious distinction MADISON, Wis. / May 22, 2024 / Business Wire / Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that the company has been certified as a 2024 Great Place To Work® for the sixth consecutive year. The certification is based on the results of a confidential employee survey to U.S.-based... Read More

Company asserts that Geneoscopy will infringe patented technology central to its Cologuard colorectal cancer screening test MADISON, Wis. / May 21, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that a District Court judge denied in part Geneoscopy’s (defendant) motion to dismiss a patent infringement lawsuit filed by Exact Sciences... Read More

First quarter highlights Delivered total first quarter revenue of $638 million, an increase of 6% on a reported and core revenue basis, including Screening revenue of $475 million and Precision Oncology revenue of $163 million Published Cologuard Plus™ test results from pivotal BLUE-C study in The New England Journal of Medicine Maintains full-year 2024 revenue and adjusted EBITDA guidance MADISON, Wis. / May 08, 2024 /... Read More

MADISON, Wis. / May 07, 2024 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the company will present six abstracts on strategies and advancements for improving colorectal cancer screening rates and outcomes during Digestive Disease Week ® (DDW) 2024, May 18-21 in Washington, D.C. This includes data on Cologuard ® , the best-in-class... Read More

MADISON, Wis. / May 01, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 15, 2024 at 4:40 p.m. ET The webcast can be accessed in the... Read More

MADISON, Wis. / Apr 15, 2024 / Business Wire / Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. He previously held leadership positions at Baxter International and 3M, where he helped... Read More

MADISON, Wis. / Apr 11, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS) (the “Company”), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the “Agreements”) with certain holders of the Company’s 0.3750% Convertible Senior Notes due 2028 (the “Existing Notes”). Pursuant to the Agreements, the... Read More

First analysis from ASCEND-2 confirms high detection rates and specificity achieved with multi-biomarker approach in most aggressive cancers and those with no standard-of-care screening test 1 MADISON, Wis. / Apr 08, 2024 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study... Read More

MADISON, Wis. / Apr 08, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and... Read More

Initiative advances precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients at the Mayo Clinic Comprehensive Cancer Center ROCHESTER, Minn. & MADISON, Wis. / Apr 04, 2024 / Business Wire / Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic... Read More

Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early MADISON, Wis. / Mar 28, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reported on data showing high sensitivity and specificity for... Read More

Company also receives national and regional Top Workplace honors from USA Today and Wisconsin State Journal MADISON, Wis. / Mar 27, 2024 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2024 Gallup Exceptional Workplace Award (GEWA). This award recognizes the most engaged workplace cultures in the world. Gallup created the... Read More

Cologuard Plus is only noninvasive test to be evaluated head-to-head against an independent fecal immunochemical test, which it significantly outperformed 20,000-participant BLUE-C study included 98 colorectal cancers and reflects racial and ethnic diversity of U.S. Company will host conference call and webcast at 8:00 a.m. ET on March 14 to discuss study results MADISON, Wis. / Mar 13, 2024 / Business Wire / Exact Sciences... Read More

In collaboration with The Blue Hat Foundation, “Box Out Colon Cancer” offers a timely spotlight on screening and prevention for the nation’s #2 cancer-related killer 1 MADISON, Wis. / Mar 07, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up... Read More

MADISON, Wis. / Feb 26, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. TD Cowen 44 th Annual Health Care Conference, Boston Fireside chat on Monday, March 4, 2024 at 1:30 p.m. ET The webcast can be accessed in the... Read More

Reports record revenue, generates positive free cash flow, expects 2024 revenue of $2.810-2.850 billion Fourth quarter and 2023 highlights Total fourth quarter revenue of $647 million, an increase of 17%, or 18% on a core revenue basis, with Screening revenue of $487 million and Precision Oncology revenue of $160 million Total 2023 revenue of $2.50 billion, an increase of 20%, or 24% on a core revenue basis, with Screening... Read More

MADISON, Wis. / Feb 01, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2023 financial results after the close of the U.S. financial markets on February 21, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results... Read More

Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion , submits next-generation Cologuard ® to FDA Announces Chief Financial Officer succession plan Highlighted announcements: Expects total fourth quarter revenue of $645.5 - $647.5 million , an increase of 17% compared to the fourth quarter of 2022, with Screening revenue of $486.0 - $487.0 million and Precision Oncology revenue of $159.5... Read More

MADISON, Wis. , Jan. 2, 2024 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. J.P. Morgan Healthcare Conference, San Francisco Presentation followed by Q&A on Monday, January 8, 2024 at 2:15 p.m. ET The webcast can be accessed in... Read More

MADISON, Wis. , Dec. 7, 2023 /PRNewswire/ -- Exact Sciences , a leading provider of cancer screening and diagnostic tests, announced today that it awarded $1.3 million to 23 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program. Grant recipients are committed to improving colorectal cancer (CRC) screening rates and making healthcare more accessible, with a focus on medically... Read More

Updated TAILORx follow-up data showing the integration of clinico-pathologic criteria and Recurrence Score ® results to refine distant recurrence risk estimates New concordance analysis supporting the generation of Oncotype DX ® results from core needle biopsy to personalize treatment decisions ADAPTcycle trial data, using Oncotype DX results and endocrine response to stratify patients, may expand the number of breast cancer... Read More

Company asserts that Geneoscopy infringed patented technology central to its Cologuard colorectal cancer screening test MADISON, Wis. , Nov. 17, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of Delaware . The lawsuit seeks damages... Read More

Reports record revenue, delivers more than a million test results, raises full-year guidance Third -quarter 2023 highlights Total third quarter revenue of $628 million , an increase of 20%, or 23% on a core revenue basis Delivered more than 1 million test results, including a record for Cologuard® and Oncotype DX® tests Full-year 2023 revenue and adjusted EBITDA guidance midpoints raised by $28 million and $25 million ,... Read More

MADISON, Wis. , Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Stifel Healthcare Conference, New York Fireside chat on Tuesday, November 14, 2023 at 10:20 a.m. ET Jefferies London Healthcare Conference, London... Read More

American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study results versus FIT at ACG High specificity for next-generation Cologuard test expected to minimize unnecessary follow-up colonoscopies, supporting positive patient experiences 1 MADISON, Wis. , Oct. 22, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading... Read More

MADISON, Wis. , Oct. 20, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer detection, genomic testing, and treatment guidance at the 2023 European Society for Medical Oncology (ESMO) Congress, October 20-24 , in Madrid, Spain . Exact Sciences will feature studies from... Read More

MADISON, Wis. , Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after the close of the U.S. financial markets on November 1, 2023 . Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results... Read More

MADISON, Wis. , Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present late-breaking data on next-generation Cologuard ® from the BLUE-C pivotal trial during the American College of Gastroenterology (ACG) Annual Meeting, taking place October 20-25, 2023 , in Vancouver, Canada . Further evidence supporting both the... Read More

MADISON, Wis. , Sept. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. Baird Global Healthcare Conference, New York Fireside chat on Tuesday, September 12, 2023 at 10:50 a.m. ET The webcast can be accessed in the investor... Read More

ComboMATCH trials will use Exact Sciences' new OncoExTra ™ therapy selection test to analyze tumor samples for participants in this large precision medicine initiative Participation in trials reinforces company's commitment to enable delivery of personalized cancer care MADISON, Wis. , Aug. 30, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today... Read More

First-of-its-kind research from the "I Am 45" poll explores why 45-year-olds are not getting screened for deadly colorectal cancer despite national screening guidelines 1,2 From lack of time to lack of health insurance, low awareness and fears of learning bad news: barriers are as unique and varied as the regions and... Read More

Reports record results, generates positive free cash flow, raises full-year guidance Second -quarter 2023 highlights Total second quarter revenue of $622 million , an increase of 19%, and $617 million of core revenue, an increase of 24% Cash provided by operating activities was $100 million and free cash flow was $66 million Full-year 2023 revenue and adjusted EBITDA guidance raised by $54 million and $63 million at the... Read More

MADISON, Wis. , July 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after the close of the U.S. financial markets on August 1, 2023 . Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results... Read More

Agreements with Broad Institute of MIT and Harvard provide exclusive license to next-generation technology for ultra-sensitive detection of molecular residual disease and ongoing research Collaboration with Baylor Scott & White creates real-world experience and evidence supporting Exact Sciences' multi-cancer early detection approach MADISON, Wis. , June 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading... Read More

BLUE-C study met all endpoints, showing improved cancer sensitivity, specificity, and precancer sensitivity 20,000-participant study reflects racial and ethnic diversity of the U.S. Company plans to complete FDA submission for next-generation Cologuard by end of 2023 MADISON, Wis. , June 20, 2023 /PRNewswire/ -- Exact Sciences... Read More

Award marks fifth consecutive year company has received prestigious distinction MADISON, Wis. , June 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that the company has been certified as a 2023 Great Place To Work ® for the fifth consecutive year. The certification is based on the results of a confidential survey open to U.S.-based... Read More

MADISON, Wis. , June 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Jefferies Healthcare Conference, New York Fireside chat on Wednesday, June 7, 2023 at 2:00 p.m. ET William Blair 43 rd Annual Growth Stock Conference,... Read More

Exact Sciences' approach in multi-cancer early detection (MCED) confirmed in first-ever, long-term, follow-up data from an MCED trial 1-2 Surveillance, Epidemiology, and End Results (SEER) program analysis shows continued, long- term confidence in prognostic value of the Oncotype DX Breast Recurrence Score ® 3 New modeling data show superior health outcomes in colorectal cancer screening with Cologuard ® compared to... Read More

MADISON, Wis. , May 17, 2023 /PRNewswire/ -- Exact Sciences , a leading provider of cancer screening and diagnostic tests, announced today that it awarded $1.1 million to 18 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program. Grant recipients are committed to improving uptake of colorectal cancer (CRC) screening and supporting affordable pathways to follow-up care for people... Read More

First quarter highlights Total first quarter revenue of $602 million , an increase of 24%, and $598 million of core revenue, an increase of 33% Full-year 2023 revenue guidance raised by $110 million at the midpoint Expect to turn free cash flow positive during 2023, ahead of previous target of 2024 Reports record results, raises full-year guidance, accelerates path to positive free cash flow MADISON, Wis. , May 9, 2023... Read More

Results of three modeling studies demonstrated that non-invasive colorectal cancer screening with Cologuard ® is more effective when compared to hypothetical blood-based screening 1-3 MADISON, Wis. , May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, presented new data supporting the company's research and innovation in colorectal cancer (CRC) during... Read More

MADISON, Wis. , May 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 10, 2023 at 6:00 p.m. ET The webcast can be accessed in the investor... Read More

Research from Exact Sciences' multi-cancer early detection (MCED) program supports advanced imaging as an optimal and potentially more efficient strategy for identifying cancerous tumor location following a positive MCED test result 1 Exact Sciences presents preliminary data showing promise of molecular residual disease (MRD) detection technologies for detection of cancer recurrence post therapy 2 MADISON, Wis. , April 12,... Read More

MADISON, Wis. , April 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after the close of the U.S. financial markets on May 9, 2023 . Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and... Read More

MADISON, Wis. , Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated exchange and purchase agreement (the "Agreement") with a holder of certain of the Company's 0.3750% Convertible Senior Notes due 2027 (the "Existing 2027 Notes") and certain of its... Read More

MADISON, Wis. , Feb. 22, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Citi's Healthcare Services, Medtech, Tools & HCIT Conference, New York Fireside chat on Wednesday, March 1, 2023 at 2:45 p.m. ET Cowen Health Care... Read More

Reports record revenue, expects revenue of $2,265 -2,315 million and positive adjusted EBITDA for full year 2023 Fourth quarter and 2022 highlights Total fourth quarter revenue of $553 million , an increase of 17% or 28% excluding COVID-19 testing, with Screening revenue of $404 million and Precision Oncology revenue of $143 million Total 2022 revenue of $2,084 million , an increase of 18% or 25% excluding COVID-19 testing,... Read More

Test Identifies Tumor DNA and RNA Alterations to Help Guide Personalized Treatments for Patients Based on Their Cancer MADISON, Wis. , Feb. 7, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of the OncoExTra™ therapy selection... Read More

MADISON, Wis. , Feb. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2022 financial results after the close of the U.S. financial markets on February 21, 2023 . Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results... Read More

Preliminary fourth quarter highlights: Expected total fourth quarter revenue, excluding COVID - 19 testing, increased 28% compared to the fourth quarter 2021, with Screening revenue of $401.8 - $402.8 million and Precision Oncology revenue of $142.9 - $143.9 million Expected total 2022 revenue, excluding COVID - 19 testing, increased 25% compared to 2021, with Screening revenue of $1,423.0 - $1,424.0 million and Precision... Read More

MADISON, Wis. , Jan. 3, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. J.P. Morgan Healthcare Conference, San Francisco Presentation followed by Q&A on Monday, January 9, 2023 at 2:15 p.m. ET The webcast can be accessed in... Read More

MADISON, Wis. , Dec. 20, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, supports recent policy changes that help increase access to recommended non-invasive colorectal cancer screening tests. These policy changes require Medicare and most commercial insurers to pay for colonoscopy after a positive Cologuard® test without cost to the patient. For most... Read More

MADISON, Wis. , Dec. 9, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today shared initial clinical validation data for its breast cancer radiation signature, Profile for the Omission of Local Adjuvant Radiotherapy (POLAR), at the 2022 San Antonio Breast Cancer Symposium ® (SABCS ® ). The meta-analysis of three independent, randomized clinical trials... Read More

New independent clinical evidence from the pivotal TAILORx and RxPONDER trials support the role of the Oncotype DX Breast Recurrence Score ® test, the only genomic test to predict chemotherapy benefit in early-stage breast cancer patients 1 , 2 , 3 , 4 Initial validation study of a new test to predict radiotherapy benefit will be highlighted in the official SABCS press program, demonstrating Exact Sciences' commitment to... Read More